

Brown (FL) Gutierrez  
Brown (SC) Gutknecht  
Bryant Hall (OH)  
Burr Hall (TX)  
Burton Hansen  
Buyer Harman  
Callahan Hart  
Calvert Hastert  
Camp Hastings (FL)  
Cannon Hastings (WA)  
Cantor Hayes  
Capito Hayworth  
Capps Hefley  
Capuano Herger  
Cardin Hill  
Carson (OK) Hilleary  
Castle Hilliard  
Chabot Hinojosa  
Chambliss Hobson  
Clay Hoeffel  
Clayton Hoekstra  
Clement Holden  
Clyburn Holt  
Coble Honda  
Collins Hooley  
Combest Horn  
Condit Hostettler  
Cooksey Houghton  
Costello Hoyer  
Cox Hulshof  
Coyne Hunter  
Cramer Hyde  
Crane Insee  
Crenshaw Isakson  
Crowley Israel  
Culberson Issa  
Cummings Istook  
Cunningham Jackson-Lee  
Davis (CA) (TX)  
Davis (FL) Jefferson  
Davis (IL) Jenkins  
Davis, Jo Ann John  
Davis, Tom Johnson (CT)  
Deal Johnson (IL)  
DeGette Johnson, E. B.  
DeLauro Johnson, Sam  
DeLay Jones (NC)  
DeMint Jones (OH)  
Deutsch Kanjorski  
Diaz-Balart Kaptur  
Dicks Keller  
Dingell Kelly  
Doggett Kennedy (MN)  
Dooley Kennedy (RI)  
Doolittle Kerns  
Doyle Kildee  
Dreier Kilpatrick  
Duncan Kind (WI)  
Dunn King (NY)  
Edwards Kingston  
Ehlers Kirk  
Ehrlich Kleczka  
Emerson Knollenberg  
Engel Kolbe  
English Kucinich  
Etheridge LaFalce  
Evans LaHood  
Everett Lampson  
Farr Langevin  
Fattah Lantos  
Ferguson Largent  
Flake Larsen (WA)  
Fletcher Larson (CT)  
Foley Latham  
Forbes LaTourette  
Fossella Leach  
Frank Levin  
Frelinghuysen Lewis (CA)  
Frost Lewis (KY)  
Gallegly Linder  
Ganske Lipinski  
Gekas LoBiondo  
Gephardt Lofgren  
Gibbons Lowey  
Gilchrest Lucas (KY)  
Gillmor Lucas (OK)  
Gilman Luther  
Gonzalez Lynch  
Goode Maloney (CT)  
Goodlatte Maloney (NY)  
Gordon Manzullo  
Goss Markey  
Graham Mascara  
Granger Matheson  
Graves Matsui  
Green (TX) McCarthy (MO)  
Green (WI) McCarthy (NY)  
Greenwood McCollum  
Grucci McCreary

McGovern  
McHugh  
McInnis  
McIntyre  
McKeon  
McNulty  
Meehan  
Meek (FL)  
Meeks (NY)  
Menendez  
Mica  
Millender-McDonald  
Miller, Dan  
Miller, Gary  
Miller, Jeff  
Mink  
Mollohan  
Moore  
Moran (KS)  
Moran (VA)  
Morella  
Murtha  
Myrick  
Napolitano  
Neal  
Nethercutt  
Ney  
Northup  
Norwood  
Nussle  
Oberstar  
Obey  
Oliver  
Ortiz  
Osborne  
Ose  
Otter  
Oxley  
Pallone  
Pascarelli  
Pastor  
Pelosi  
Pence  
Peterson (MN)  
Peterson (PA)  
Petri  
Phelps  
Pickering  
Pitts  
Platts  
Pombo  
Pomeroy  
Portman  
Price (NC)  
Pryce (OH)  
Putnam  
Radanovich  
Rahall  
Ramstad  
Rangel  
Regula  
Rehberg  
Reyes  
Reynolds  
Riley  
Rivers  
Rodriguez  
Roemer  
Rogers (KY)  
Rogers (MI)  
Rohrabacher  
Ros-Lehtinen  
Ross  
Roukema  
Roybal-Allard  
Royce  
Rush  
Ryan (WI)  
Ryun (KS)  
Sabo  
Sanchez  
Sanders  
Sandlin  
Sawyer  
Saxton  
Schaffer  
Schakowsky  
Schiff  
Schrock  
Scott  
Sensenbrenner  
Sessions  
Shadegg  
Shaw  
Shays  
Sherman  
Sherwood  
Shimkus

Shows  
Shuster  
Simmons  
Simpson  
Skeen  
Skeltan  
Slaughter  
Smith (MI)  
Smith (NJ)  
Smith (TX)  
Smith (WA)  
Snyder  
Solis  
Souder  
Spratt  
Stearns  
Stenholm  
Strickland  
Stump  
Stupak  
Sununu  
Sweeney  
Tancredo

Blumenauer  
Brown (OH)  
Conyers  
Delahunt  
Eshoo  
Filner  
Hinchey

Carson (IN)  
Cubin  
DeFazio

Tanner  
Tauscher  
Tauzin  
Taylor (MS)  
Taylor (NC)  
Terry  
Thomas  
Thompson (CA)  
Thompson (MS)  
Thornberry  
Thune  
Thurman  
Tiahrt  
Tiberi  
Tierney  
Toomey  
Towns  
Traficant  
Turner  
Udall (CO)  
Udall (NM)  
Upton  
Visclosky

#### NAYS—20

Jackson (IL)  
Lee  
Lewis (GA)  
McDermott  
McKinney  
Miller, George  
Nadler

#### NOT VOTING—7

Ford  
Quinn  
Rothman  
Wexler

□ 2154

So the bill was passed.

The result of the vote was announced as above recorded.

A motion to reconsider was laid on the table.

#### REPORT ON RESOLUTION PROVIDING FOR CONSIDERATION OF H.R. 3210, TERRORISM RISK PROTECTION ACT

Mrs. MYRICK, from the Committee on Rules, submitted a privileged report (Rept. No. 107-304) on the resolution (H. Res. 297) providing for consideration of the bill (H.R. 3210) to ensure the continued financial capacity of insurers to provide coverage for risks from terrorism, which was referred to the House Calendar and ordered to be printed.

#### REMOVAL OF NAME OF MEMBER AS COSPONSOR OF H.R. 3323

Mr. McDERMOTT. Mr. Speaker, I ask unanimous consent to have my name removed as a cosponsor of H.R. 3323.

The SPEAKER pro tempore (Mr. SIMPSON). Is there objection to the request of the gentleman from Washington?

There was no objection.

#### SPECIAL ORDERS

The SPEAKER pro tempore (Mr. SIMPSON). Under the Speaker's announced policy of January 3, 2001, and under a previous order of the House, the following Members will be recognized for 5 minutes each.

The SPEAKER pro tempore. Under a previous order of the House, the gentleman from Michigan (Mr. CONYERS) is recognized for 5 minutes.

(Mr. CONYERS addressed the House. His remarks will appear hereafter in the Extensions of Remarks.)

The SPEAKER pro tempore. Under a previous order of the House, the gentleman from Indiana (Mr. SOUDER) is recognized for 5 minutes.

(Mr. SOUDER addressed the House. His remarks will appear hereafter in the Extensions of Remarks.)

The SPEAKER pro tempore. Under a previous order of the House, the gentlewoman from the District of Columbia (Ms. NORTON) is recognized for 5 minutes.

(Ms. NORTON addressed the House. Her remarks will appear hereafter in the Extensions of Remarks.)

The SPEAKER pro tempore. Under a previous order of the House, the gentleman from Iowa (Mr. GANSKE) is recognized for 5 minutes.

(Mr. GANSKE addressed the House. His remarks will appear hereafter in the Extensions of Remarks.)

□ 2200

#### GLUCOPHAGE

The SPEAKER pro tempore (Mr. SIMPSON). Under a previous order of the House, the gentleman from New Jersey (Mr. PALLONE) is recognized for 5 minutes.

Mr. PALLONE. Mr. Speaker, I rise on the House floor to express my deep concerns regarding the lobbying efforts of Bristol-Myers-Squibb to block access to affordable generic alternatives to their blockbuster diabetes drug Glucophage.

The FDA's Office of Generic Drugs has numerous generic versions of this diabetes drug awaiting approval. However, the office is unable to allow these generics onto the market due to Bristol's monopoly. There are no patents blocking the approval of generics in this case. The only obstacle is a result in the loophole in the Waxman-Hatch exclusivity. It allows Bristol to obtain 3 years of Waxman-Hatch exclusivity in addition to 6 months of pediatric exclusivity for a new indication, the use of this drug for treatment of Type 2 diabetes in pediatric patients ages 10 to 16 years.

Mr. Speaker, the pediatric research conducted on this drug has yielded useful results for pediatric use. However, Bristol should not be allowed a total of 3 years plus 6 months of exclusivity for changing its label to indicate pediatric use. This only leads to 3 years and 6 months more of keeping valuable generics off the market.

The FDA regulations authorize a generic manufacturer to carve out of its labeling indications that are protected by patents or exclusivity. Therefore, there does not seem to be any reason why the generic forms of this diabetes drug cannot be approved now without the pediatric indication.